GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Endonovo Therapeutics Inc (OTCPK:ENDV) » Definitions » Shiller PE Ratio

Endonovo Therapeutics (Endonovo Therapeutics) Shiller PE Ratio : (As of Jun. 02, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Endonovo Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Endonovo Therapeutics Shiller PE Ratio Historical Data

The historical data trend for Endonovo Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Endonovo Therapeutics Shiller PE Ratio Chart

Endonovo Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Endonovo Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Endonovo Therapeutics's Shiller PE Ratio

For the Biotechnology subindustry, Endonovo Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Endonovo Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Endonovo Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Endonovo Therapeutics's Shiller PE Ratio falls into.



Endonovo Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Endonovo Therapeutics's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Endonovo Therapeutics's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0/129.4194*129.4194
=0.000

Current CPI (Dec. 2023) = 129.4194.

Endonovo Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 -696.030 99.695 -903.558
201406 -39.625 100.560 -50.997
201409 2.085 100.428 2.687
201412 -2.738 99.070 -3.577
201503 -10.000 99.621 -12.991
201506 -10.000 100.684 -12.854
201509 -10.000 100.392 -12.891
201512 -50.000 99.792 -64.844
201603 -10.000 100.470 -12.881
201606 -10.000 101.688 -12.727
201609 -20.000 101.861 -25.411
201612 -10.000 101.863 -12.705
201703 -50.000 102.862 -62.909
201706 10.000 103.349 12.523
201709 -30.000 104.136 -37.284
201712 20.000 104.011 24.886
201803 -1.890 105.290 -2.323
201806 -3.595 106.317 -4.376
201809 -20.000 106.507 -24.303
201812 2.240 105.998 2.735
201903 -4.990 107.251 -6.021
201906 -13.570 108.070 -16.251
201909 -1.810 108.329 -2.162
201912 -5.830 108.420 -6.959
202003 -0.140 108.902 -0.166
202006 -0.170 108.767 -0.202
202009 -0.070 109.815 -0.082
202012 -0.083 109.897 -0.098
202103 -0.060 111.754 -0.069
202106 -0.020 114.631 -0.023
202109 -0.020 115.734 -0.022
202112 0.050 117.630 0.055
202203 -0.030 121.301 -0.032
202206 -0.020 125.017 -0.021
202209 -0.004 125.227 -0.004
202212 -0.080 125.222 -0.083
202303 0.000 127.348 0.000
202306 0.007 128.729 0.007
202309 -0.002 129.860 -0.002
202312 0.000 129.419 0.000

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Endonovo Therapeutics  (OTCPK:ENDV) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Endonovo Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Endonovo Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Endonovo Therapeutics (Endonovo Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
6320 Canoga Avenue, 15th Floor, Woodland Hills, CA, USA, 91367
Endonovo Therapeutics Inc is an us-based biotechnology company that focuses on the business of biomedical research and development, particularly in regenerative medicine, which has included the development of its proprietary square waveform device. It is engaged in developing the Immunotronics platform which is non-implantable, a non-invasive medical device to target inflammatory conditions in vital organs; and the Cytotronics platform which uses Time-Varying Electromagnetic Fields technology for the creation of cell-based therapies. The company generates its revenue through its technology licensing and commercialization activities.
Executives
Alan Brian Collier director, 10 percent owner, officer: CEO 6320 CANOGA AVENUE, 15TH FLOOR, WOODLAND HILLS CA 91367
Michael Scott Mann 10 percent owner, officer: President 6320 CANOGA AVENUE, WOODLAND HILLS CA 91367

Endonovo Therapeutics (Endonovo Therapeutics) Headlines